ReviewFrontiers in cardiovascular medicine2019
Toward Regeneration of the Heart: Bioengineering Strategies for Immunomodulation.
Review in Frontiers in cardiovascular medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 80 citations in OpenAlex.
- Multimodal characterization of sustained bioagent release from an epicardial depot for long-term biomaterial incorporation.Biomaterials · 2026Article
- Article
- Enhancing anti-fibrotic therapy: nanomedicine approaches to overcome current limitations.Materials today. Bio · 2026Review
- Mitochondrial transplant activates CaStem cell research & therapy · 2026Article
- Lessons of Macrophage-Associated Heart Regeneration in Fish, Amphibians, and Neonatal Mice, Applied to Adult Mice: A Perspective on α-Gal Nanoparticles.International journal of molecular sciences · 2026Review
- Toll-like receptor 4 induces trained innate immune tolerance in the heart in a model of stress-induced cardiomyopathy.Cardiovascular research · 2025Article
- Current status and new horizons in stem cell therapy in cardiovascular regenerative medicine (CaVaReM): an update.European journal of medical research · 2025Review
- Simulated Effects of Acute Left Ventricular Myocardial Infarction on Mitral Regurgitation in an Ovine Model.Journal of biomechanical engineering · 2024Article
- Integrating Vascular Phenotypic and Proteomic Analysis in an Open Microfluidic Platform.ACS nano · 2024Article
- Hypothermic and cryogenic preservation of cardiac tissue-engineered constructs.Biomaterials science · 2024Article
- Injectable Hydrogels in Cardiovascular Tissue Engineering.Polymers · 2024Review
- Evolving Strategies for Extracellular Vesicles as Future Cardiac Therapeutics: From Macro- to Nano-Applications.International journal of molecular sciences · 2024Review
- Advancing cardiac regeneration through 3D bioprinting: methods, applications, and future directions.Heart failure reviews · 2024Review
- Hydrogel-based cardiac repair and regeneration function in the treatment of myocardial infarction.Materials today. Bio · 2024Review
- Ameliorating impaired cardiac function in myocardial infarction using exosome-loaded gallic-acid-containing polyurethane scaffolds.Bioactive materials · 2024Article
- Three-Dimensional Bioprinting in Cardiovascular Disease: Current Status and Future Directions.Biomolecules · 2023Review
- A Review on the Applications of Natural Biodegradable Nano Polymers in Cardiac Tissue Engineering.Nanomaterials (Basel, Switzerland) · 2023Review
- Mending a broken heart by biomimetic 3D printed natural biomaterial-based cardiac patches: a review.Frontiers in bioengineering and biotechnology · 2023Review
- Immunomodulating Hydrogels as Stealth Platform for Drug Delivery Applications.Pharmaceutics · 2022Review
- Progress in Bioengineering Strategies for Heart Regenerative Medicine.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Myocardial Infarction (MI) is the most common cardiovascular disease. An average-sized MI causes the loss of up to 1 billion cardiomyocytes and the adult heart lacks the capacity to replace them. Although post-MI treatment has dramatically improved survival rates over the last few decades, more than 20% of patients affected by MI will subsequently develop heart failure (HF), an incurable condition where the contracting myocardium is transformed into an akinetic, fibrotic scar, unable to meet the body's need for blood supply. Excessive inflammation and persistent immune auto-reactivity have been suggested to contribute to post-MI tissue damage and exacerbate HF development. Two newly emerging fields of biomedical research, immunomodulatory therapies and cardiac bioengineering, provide potential options to target the causative mechanisms underlying HF development. Combining these two fields to develop biomaterials for delivery of immunomodulatory bioactive molecules holds great promise for HF therapy. Specifically, minimally invasive delivery of injectable hydrogels, loaded with bioactive factors with angiogenic, proliferative, anti-apoptotic and immunomodulatory functions, is a promising route for influencing the cascade of immune events post-MI, preventing adverse left ventricular remodeling, and offering protection from early inflammation to fibrosis. Here we provide an updated overview on the main injectable hydrogel systems and bioactive factors that have been tested in animal models with promising results and discuss the challenges to be addressed for accelerating the development of these novel therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.